On November 21, 2024, BioVie filed a registration statement with the SEC to offer up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V, issued in connection with multiple offerings throughout 2024.The company will not receive proceeds from the resale of shares by the selling stockholders. However, it will receive nominal cash from the exercise of warrants, which will be used for working capital and general corporate purposes. BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 per share on November 19, 2024.Investors are advised to review the "Risk Factors" section in the prospectus for potential risks associated with investing in these securities. The registration is part of BioVie's strategy to satisfy registration rights granted to the selling stockholders.

On November 21, 2024, BioVie filed a registration statement with the SEC to offer up to 7,711,613 shares of Class A common stock for resale by selling stockholders. These shares are issuable upon the exercise of various warrants, including Private Placement I and II Warrants, and Placement Agent Warrants I-V, issued in connection with multiple offerings throughout 2024.The company will not receive proceeds from the resale of shares by the selling stockholders. However, it will receive nominal cash from the exercise of warrants, which will be used for working capital and general corporate purposes. BioVie's common stock is traded on Nasdaq under the symbol "BIVI," with a closing price of $3.51 per share on November 19, 2024.Investors are advised to review the "Risk Factors" section in the prospectus for potential risks associated with investing in these securities. The registration is part of BioVie's strategy to satisfy registration rights granted to the selling stockholders.